Sanoculis Ltd
11
2
3
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
This Follow-up Extension Study is Aimed to Monitor the Long-term IOP-lowering Performance/Efficacy and Safety of the MINT® Procedure in Open Angle Glaucoma Eyes.
Role: lead
The Minimally Invasive Micro Sclerostomy (MIMS®) System is Intended for the Reduction of Elevated Intraocular Pressure (IOP): The Minimally Invasive Micro Sclerostomy (MIMS®) System is Intended for the Reduction of Elevated Intraocular Pressure (IOP)
Role: lead
MIMS® Retrospective Chart Review
Role: lead
Minimally Invasive Nasal Trabeculostomy: Long-Term Follow-Up Extension Study
Role: lead
Inferonasal MIMS® Procedure: Long-Term Follow-Up Extension Study
Role: lead
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
Role: lead
Minimally Invasive Micro Sclerostomy (MIMS®) Inferonasal Procedure - Performance Evaluation Study
Role: lead
Minimally Invasive Nasal Trabeculostomy - Performance and Safety Evaluation Study
Role: lead
Minimally Invasive Micro Sclerostomy: Performance and Safety Evaluation Study
Role: lead
Minimally Invasive Micro Sclerostomy First in Man Safety and Preliminary Performance Study
Role: lead
Minimally Invasive Micro Sclerostomy: Safety and Preliminary Performance Study
Role: lead
All 11 trials loaded